Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Date:9/19/2011

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that management will present at the JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 11:00 A.M. ET in New York, NY.  David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only.  Delcath will offer a live webcast and subsequent archived replay of its presentation, which may be accessed at http://www.delcath.com/investors/events/.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

Media Contact:Doug Sherk/Gregory Gin

Janine McCargoEVC Group

EVC Group415-568-4887/646-445-4801

646-688-0425
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017  Pennsylvania Secretary of Health Dr. ... marijuana growers/processors and dispensaries are now available on ... Permit applications will be accepted from February 20 ... an important step forward in getting this valuable ... Murphy said. "We,ve developed a thorough application that ...
(Date:1/17/2017)... , Jan. 17, 2017  From the company that brought ... industry fourteen years ago, comes a new line of companion animal ... the world leader in equine first aid, has developed two sizes ... USA , Inc. Featuring a small and ... savvy company and rodeo family, is not a newcomer to working ...
(Date:1/17/2017)... , Jan. 17, 2016  Attorney Advertising -- Bronstein, Gewirtz ... purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the "Company") (NASDAQ: ... additional information and assist the investigation by visiting the firm,s ... Anthera and certain of its officers and/or directors have violated ... 1934. ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
(Date:1/17/2017)... , ... January 17, 2017 , ... SC&H Group, a ... as a Principal in its IT Advisory Services practice . Rossi is the ... as market demand for strategic IT guidance grows, and the practice continues to expand.     ...
(Date:1/17/2017)... Westford, Mass. (PRWEB) , ... January 17, 2017 ... ... management company to visualize, detect, and eliminate cyber threats in real-time, today announced ... and Solutions provider, headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... offices in Tyler, has announced the latest beneficiary of their thriving community involvement ... nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. Donations to ...
(Date:1/17/2017)... ... January 17, 2017 , ... Many people make New Year’s resolutions or renew their ... is making it easier for people who want to kick off 2017 with better ... existing patients. , These special offers include: , , A ...
Breaking Medicine News(10 mins):